Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

English version České info

When taken consistently, PrEP has been shown to reduce the risk of HIV infection by up to 92% in people who are at high risk. However, PrEP is much less effective if it is not taken consistently. To improve adherence to the drug regimen, several new drug delivery systems, that include novel gel formulations and long-acting delivery systems, are being evaluated. In this manuscript, we used BLT humanized mice, an in vivo model of vaginal HIV transmission, to evaluate two novel delivery systems for HIV prevention. In the first approach, we combined the highly efficient encapsulation of antiretroviral drugs into nanoparticles with a thermosensitive gel that remains liquid at room temperature and solidifies at body temperature. Our results showed that this delivery system provided significant protection from HIV vaginal infection. In a second approach, we evaluated a long-acting nanoparticle formulation for coitus-independent protection from HIV acquisition. Our results showed that a single injection of the long-acting antiviral drug also resulted in reduced HIV infection. However, protection was not complete and transmission was concealed by a significant delay in the onset of plasma viremia that could result in superinfection by two different viruses administered up to four weeks apart.

Vyšlo v časopise: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog 11(8): e32767. doi:10.1371/journal.ppat.1005075
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1005075

Souhrn

Zdroje

1. WHO. Global summary of AIDS epidemic 2013 http://www.who.int/hiv/data/epi_core_dec2014.png?ua=12014.

2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. Epub 2010/07/21. doi: 10.1126/science.1193748 20643915; PubMed Central PMCID: PMCPmc3001187.

3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. Epub 2010/11/26. doi: 10.1056/NEJMoa1011205 21091279; PubMed Central PMCID: PMCPmc3079639.

4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. Epub 2012/07/13. doi: 10.1056/NEJMoa1108524 22784037; PubMed Central PMCID: PMCPmc3770474.

5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. doi: 10.1056/NEJMoa1110711 22784038.

6. D'Cruz OJ, Uckun FM. Vaginal microbicides and their delivery platforms. Expert opinion on drug delivery. 2014;11(5):723–40. Epub 2014/02/11. doi: 10.1517/17425247.2014.888055 24506783.

7. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Current opinion in HIV and AIDS. 2013;8(6):565–71. Epub 2013/10/09. doi: 10.1097/coh.0000000000000002 24100877; PubMed Central PMCID: PMCPmc3815009.

8. Vermund SH, Van Damme L. HIV prevention in women: next steps. Science. 2011;331(6015):284. Epub 2011/01/22. doi: 10.1126/science.331.6015.284-a 21252332.

9. Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS (Auckland, NZ). 2011;3:35–44. Epub 2011/11/19. doi: 10.2147/hiv.s14559 22096405; PubMed Central PMCID: PMCPmc3218710.

10. Baert L, van 't Klooster G, Dries W, Francois M, Wouters A, Basstanie E, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009;72(3):502–8. Epub 2009/03/31. doi: 10.1016/j.ejpb.2009.03.006 19328850.

11. van 't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, van Velsen F, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54(5):2042–50. Epub 2010/02/18. doi: 10.1128/aac.01529-09 20160045; PubMed Central PMCID: PMCPmc2863620.

12. Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, et al. A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. Clin Pharmacol Ther. 2014;96:314–23. Epub 2014/05/28. doi: 10.1038/clpt.2014.118 24862215.

13. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. Science. 2014;343(6175%U http://www.sciencemag.org/content/343/6175/1151.abstract):1151–4. doi: 10.1126/science.1248707 24594934

14. Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra4. Epub 2015/01/16. doi: 10.1126/scitranslmed.3010298 25589630.

15. Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, Garcia-Lerma JG, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra5. Epub 2015/01/16. doi: 10.1126/scitranslmed.3010297 25589631.

16. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol. 2012;86(5):2715–28. Epub 2011/12/23. doi: 10.1128/jvi.06157-11 22190722; PubMed Central PMCID: PMCPmc3302286.

17. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273–89. Epub 2009/06/03. doi: 10.1084/jem.20090378 19487424; PubMed Central PMCID: PMCPmc2715054.

18. Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS reviews. 2011;13(3):135–48. Epub 2011/07/30. 21799532; PubMed Central PMCID: PMCPmc3741405.

19. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006;12(11):1316–22. Epub 2006/10/24. 17057712.

20. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12(11):786–98. Epub 2012/10/13. doi: 10.1038/nri3311 23059428; PubMed Central PMCID: PMCPmc3749872.

21. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV. Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol. 2008;324:149–65. Epub 2008/05/17. 18481459.

22. Deruaz M, Luster AD. BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis. 2013;208 Suppl 2:S131–6. Epub 2013/10/30. doi: 10.1093/infdis/jit318 24151319; PubMed Central PMCID: PMCPMC3807970.

23. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol. 2011;85(15):7582–93. Epub 2011/05/20. doi: 10.1128/jvi.00537-11 21593172; PubMed Central PMCID: PMCPmc3147928.

24. Olesen R, Wahl A, Denton PW, Garcia JV. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol. 2011;88(2):195–203. Epub 2011/01/25. doi: 10.1016/j.jri.2010.11.005 21256601; PubMed Central PMCID: PMCPmc3407567.

25. Denton PW, Garcia JV. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol. 2012;20(6):268–74. Epub 2012/04/17. doi: 10.1016/j.tim.2012.03.007 22503637; PubMed Central PMCID: PMCPmc3680353.

26. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16. Epub 2008/01/18. doi: 10.1371/journal.pmed.0050016 18198941; PubMed Central PMCID: PMCPmc2194746.

27. Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One. 2010;5(1):e8829. Epub 2010/01/26. doi: 10.1371/journal.pone.0008829 20098623; PubMed Central PMCID: PMCPmc2809117.

28. US-FDA. Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. Silver Spring, MD: http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM312279.pdf, 2012.

29. Adams JL, Kashuba AD. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):451–62. doi: 10.1016/j.bpobgyn.2012.01.004 22306523; PubMed Central PMCID: PMC3662244.

30. Roy S, Gourde P, Piret J, Desormeaux A, Lamontagne J, Haineault C, et al. Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother. 2001;45(6):1671–81. 11353610; PubMed Central PMCID: PMC90530.

31. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58(2):409–26. 15296964.

32. Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 2012;96(3):430–6. doi: 10.1016/j.antiviral.2012.09.015 23041201; PubMed Central PMCID: PMC3513487.

33. Aka-Any-Grah A, Bouchemal K, Koffi A, Agnely F, Zhang M, Djabourov M, et al. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur J Pharm Biopharm. 2010;76(2):296–303. Epub 2010/07/27. doi: 10.1016/j.ejpb.2010.07.004 20656027.

34. Cu Y, Booth CJ, Saltzman WM. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release. 2011;156(2):258–64. doi: 10.1016/j.jconrel.2011.06.036 21763739; PubMed Central PMCID: PMC3220785.

35. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res. 2009;26(3):502–11. doi: 10.1007/s11095-008-9765-2 19002569.

36. Steinbach JM, Weller CE, Booth CJ, Saltzman WM. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release. 2012;162(1):102–10. doi: 10.1016/j.jconrel.2012.06.008 22705461; PubMed Central PMCID: PMC3543782.

37. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nature materials. 2009;8(6):526–33. doi: 10.1038/nmat2444 19404239; PubMed Central PMCID: PMC2693358.

38. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010;65(10):2183–7. doi: 10.1093/jac/dkq318 20729545; PubMed Central PMCID: PMC2941676.

39. Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79. doi: 10.1126/scitranslmed.3003453 22700955; PubMed Central PMCID: PMC3817739.

40. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The Uptake and Intracellular Fate of PLGA Nanoparticles in Epithelial Cells. Biomaterials. 2009;30(14):2790–8. 19232712. doi: 10.1016/j.biomaterials.2009.01.057

41. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–27. Epub 2009/11/26. doi: 10.1128/aac.00986-09 19933797; PubMed Central PMCID: PMCPmc2812151.

42. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S122–9. Epub 2013/06/21. doi: 10.1097/QAI.0b013e3182986f69 23764623; PubMed Central PMCID: PMCPmc3710117.

43. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–7. Epub 2002/10/18. 12383665.

44. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. doi: 10.1056/NEJMoa1202614 22784040; PubMed Central PMCID: PMC3687217.

45. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2015;372(6):509–18. Epub 2015/02/05. doi: 10.1056/NEJMoa1402269 25651245.

46. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198. doi: 10.1186/1471-2334-9-198 20003214; PubMed Central PMCID: PMC2807870.

47. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, et al. Generation of HIV latency in humanized BLT mice. J Virol. 2012;86(1):630–4. Epub 2011/10/21. doi: 10.1128/jvi.06120-11 22013053; PubMed Central PMCID: PMCPmc3255928.

48. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med. 2007;204(4):705–14. Epub 2007/03/29. 17389241; PubMed Central PMCID: PMCPmc2118553.

49. Wei BL, Denton PW, O'Neill E, Luo T, Foster JL, Garcia JV. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol. 2005;79(9):5705–12. Epub 2005/04/14. 15827185; PubMed Central PMCID: PMCPmc1082736.

50. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog. 2013;9(3):e1003242. Epub 2013/04/05. doi: 10.1371/journal.ppat.1003242 23555255; PubMed Central PMCID: PMCPmc3610649.

51. Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, Chateau M, et al. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 2012;8(6):e1002732. Epub 2012/06/28. doi: 10.1371/journal.ppat.1002732 22737068; PubMed Central PMCID: PMCPmc3380612.